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Candida endocarditis is a life-threatening, opportunistic fungal infection of the 
endocardium. The mortality rate of Candida endocarditis is approximately 50% and 
has been increasing in incidence over recent years. Historically, amphotericin B and 
flucytosine has been considered the standard of treatment for candida endocarditis, 
but is limited by safety concerns of amphotericin B, primarily nephrotoxicity and 
hepatotoxicity. Echinocandins, such as micafungin, have demonstrated similar 
efficacy in other forms of invasive candidiasis with better safety profiles, but there 
have been no large-scale or direct comparison trials. In this review, we summarize 
existing data between micafungin, an echinocandin, vs. amphotericin B and 
flucytosine in the setting of candida endocarditis. The information extrapolated will 
determine if micafungin is an appropriate comparator to amphotericin B and 
flucytosine for the primary treatment of candida endocarditis.
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Chapter 1 – Introduction 
1.1 Background 
 Fungal infective endocarditis is now increasing in incidence due to a growing 
number of at-risk patients, which include intravenous drug users and 
immunocompromised individuals.1,2 Worldwide, the prevalence rate of infective 
endocarditis in 2016 was 6.7 per 100,000 persons, with an incidence rate of 15.8 per 
100,000 persons.3 Approximately 2-4% of these cases are fungal infective 
endocarditis, primarily through complications of fungaemia, which, in recent years, 
has increased by 128%.2,4 The most common causative agent, Candida albicans, 
manifests within three subsets of endocarditis: native valve endocarditis, prosthetic 
valve endocarditis, and cardiac-device related endocarditis.1,5 Current guidelines 
endorsed by the Infectious Diseases Society of America (IDSA) recommend that 
these subsets of endocarditis be treated with surgical replacement of the infected 
valves and/or cardiac devices;1 however, two separate meta-analyses performed by 
the International Collaboration of Endocarditis-Prospective Cohort Study showed that 
among a cohort study of seventy cases, mortality rates between medical therapy alone 
and adjunctive surgical therapy after medical therapy were similar.4,6 In conjunction 
with this data provided by the two largest prospective studies of Candida infective 
endocarditis, not all patients are eligible for surgical intervention due to a myriad of 
reasons, which elicits an outstanding need for standardized, effective pharmacologic 
management.4,6  
In regard to current pharmacologic guidelines, the IDSA recommends that 
patients are initially started on either lipid formulations of amphotericin B, with or 
without flucytosine, or a high-dose echinocandin (i.e. caspofungin 150 mg daily, 
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micafungin 150 mg daily, or anidulafungin 200 mg daily).4,7 Upon clearance of 
fungaemia, step-down therapy to an azole is recommended after susceptibility testing, 
followed by valve and/or cardiac device replacement; however, in the instance of 
surgical contraindications, fluconazole is also used as the main agent for long-term 
suppression therapy.4 Yet, despite following these recommendations, mortality for 
patients have been estimated to be as high as 80% in published cases, prompting a 
need for a more comprehensive understanding of the disease and its treatment 
modalities.4,8  
 Amphotericin B had historically been the standard of care for several 
opportunistic fungal infections including invasive candidiasis, cryptococcal 
meningitis, and aspergillosis.9 It was the first broad antifungal agent developed for 
treating such diseases through its ability to bind to ergosterol in the fungal cell 
membrane, leading to the formation of pores, ion leakage, and, ultimately, fungal cell 
death.9 Although demonstrating an ability to target most Candida strains, except for 
Candida lusitaniae, amphotericin B not only has been known to produce common and 
severe toxicities, but also has been ineffective at penetrating into fibrin clots and 
vegetations associated with Candida endocarditis biofilms.1,7 Furthermore, antifungal 
monotherapy, specifically with amphotericin B, without adjunctive surgery has been 
associated with the poorest patient outcomes when compared to medical antifungal 
combination therapy with or without adjunctive surgery.1 However, with liposomal 
formulations of amphotericin B, which is comprised of hydrogenated soy 
phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol, this agent has 
shown an ability to maintain its antifungal properties by penetrating the extracellular 
membrane to target fungal cells, as well as reducing dose-limiting toxicities 
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associated with amphotericin B, most markedly nephrotoxicity, infusion-related 
reactions, and hepatotoxicity.9 Additionally, the liposomal formulation of 
amphotericin B, compared to amphotericin B deoxycholate, has demonstrated better 
abilities at addressing the issues associated with the development of biofilms.9 
 Additionally, flucytosine, another antifungal agent, is commonly given in 
combination with other antifungal agents, most commonly amphotericin B while 
treating refractory Candida infections, including Candida endocarditis and 
endophthalmitis.7 Current literature suggests that positive clinical outcomes are more 
associated with combination antifungal therapy of amphotericin B and flucytosine 
compared to antifungal monotherapy of either amphotericin B or flucytosine.1 In fact, 
flucytosine monotherapy has been shown to rapidly produce drug-resistant strains of 
Candida.1 The success from this combination therapy stems from the synergistic 
antifungal effects provided through the addition of flucytosine, which, has 
demonstrated broad antifungal activity against most Candida species, except for 
Candida krusei.1,7  
 While this combination therapy has shown promising clinical results, the 
ability of these antifungal agents to penetrate biofilms of Candida species other than 
Candida albicans is poor compared to the abilities of the echinocandins.10 
Echinocandins are a newer class of antifungal agents that block the production of 1,3-
β-D-glucan, which is an essential component of the fungal cell wall, and have 
demonstrated their activity against almost all strains of Candida species.7 Each of the 
three existent echinocandins, micafungin, caspofungin, and anidulafungin, has 
demonstrated efficacy in the treatment of invasive candidiasis.7 In addition to several 
case reports and case series that demonstrate the efficacy of echinocandins in treating 
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Candida endocarditis, there have been in vitro studies that have also shown successful 
elimination of model Candida biofilms that mimic vegetations residing in the 
endocardium.1,6,10 The importance of penetrating these biofilms is clinically 
significant because the biofilms are associated with drug resistance, which ultimately 
lead to treatment failure.10 Through eradication of the biofilms in the heart or affected 
intravascular devices, it may be possible for Candida endocarditis to be treated 
without the need for adjuvant surgery, which would possibly allow for preservation of 
the infected intravascular devices and/or remove the necessity for valve surgery in the 
setting of Candida endocarditis.10  
Another benefit of this class of medication is its safety—compared to 
liposomal amphotericin B, the echinocandins have fewer adverse effects, most 
notably lacking nephrotoxicity.7 Since echinocandins primary route of elimination 
from the body is through nonenzymatic degradation, they do not require dosage 
adjustments for patients with renal insufficiency or dialysis;7 however, caspofungin 
and micafungin undergo minimal hepatic metabolism, with only caspofungin having 
dosage reduction recommendations for patients with moderate to severe hepatic 
insufficiency.7 
 Current treatment recommendations supported by the IDSA are based off of a 
meta-analysis of currently available literature; however, the evidence for their 
recommendations are derived only from case reports and case series.1 There have 
been no prospective or randomized trials performed that compare amphotericin B 
combination therapy to echinocandin-based therapy in the setting of Candida 
endocarditis.1,6 With such scarce clinical data within this realm of invasive fungal 
disease, a prospective, randomized, double-blind, international multi-centre, non-
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inferiority trial is proposed to compare the efficacy and safety between liposomal 
amphotericin B with flucytosine and high-dose micafungin for the primary treatment 
of Candida endocarditis. Since amphotericin B with flucytosine is limited in its use 
through adverse events, micafungin would provide an appropriate alternative therapy 
in the primary treatment of Candida endocarditis.  
1.2 Problem Statement 
 Current recommendations endorsed by the ISDA for the primary treatment of 
Candida endocarditis is either liposomal amphotericin B, with or without flucytosine, 
or a high-dose echinocandin;7 however, there are currently no clinical data or trials 
comparing the efficacy of these recommendations.6 Amphotericin B-based therapy 
has long been considered the gold standard of treatment for Candida endocarditis due 
to its historical use and multiple cases of documented success, but remains 
cumbersome in its use due to its nephrotoxicity, even after the development of its less 
nephrotoxic liposomal formulation.6 However, with an attractive safety profile, in 
vitro studies demonstrating success against Candida biofilm models, and comparison 
studies revealing non-inferiority to the amphotericin B-based therapy in the setting of 
candidemia, echinocandins show potential of being an alternative primary treatment 
for Candida endocarditis.6 The absence of prospective, randomized control trials 
warrants a study to determine the safety and efficacy between these two treatments in 
the setting of Candida endocarditis.  
1.3 Goals and Objectives 
 The proposed study aims to determine if micafungin would be an appropriate 
primary alternative pharmacologic treatment to liposomal amphotericin B with 
flucytosine in the setting of Candida endocarditis. The goal of this study will be to 
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evaluate the outcomes between micafungin-based therapy and liposomal amphotericin 
B-based therapy for the primary treatment of Candida endocarditis by (i) determining 
non-inferiority of all-cause mortality from initiation of medication to day fifty-six, (ii) 
measuring time to clearance of candidemia, (iii) assessing safety through drug-related 
adverse effects, and (iv) quantifying the incidence of relapse following initiation of 
maintenance therapy. 
The primary study outcome, all-cause mortality from initiation of medication 
to day fifty-six of treatment, will be used to determine non-inferiority between the two 
proposed pharmacological regimens. The secondary outcomes will consist of 
measuring time to clearance of candidemia, assessing the safety profile through 
adverse side effects, and identifying the incidence of Candida endocarditis relapse 
after the initiation of step-down maintenance therapy. The information collected 
through the secondary outcomes will allow for a better understanding of optimal 
dosing for the two antifungal regimens.  
1.4 Hypothesis 
 We hypothesize that micafungin will be non-inferior in all-cause mortality to 
day fifty-six in the treatment of Candida endocarditis when compared to liposomal 
amphotericin B with flucytosine. 
1.5 Definitions 
 Infective endocarditis was defined according to the modified Duke criteria.11 
Probable and proven Candida endocarditis were defined according to both the 
modified Duke Criteria and EORTC/MSG.5,12 Candida endocarditis-related death was 
defined as the patient having signs of endocarditis at the time of death, meaning 
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positive blood cultures for Candida species and/or one other major criterion, or three 
minor criteria per the modified Duke criteria.11,13 
Table 1. Definition of Candida Endocarditis per Modified Duke Criteria 
Proven Candida Endocarditis Probable Candida Endocarditis 
Pathologic criteria: 
1. Candida species demonstrated 
by culture or histologic 
examination of a vegetation, 
embolized vegetation, or 
intracardiac abscess specimen; or 
2. Pathologic lesions—vegetation 
or intracardiac abscess 
confirmed by histologic 
examination showing active 
endocarditis 
1. 1 major and 1 minor criterion; or 
Clinical criteria: 
1. 2 major criteria; or 
2. 1 major criterion and 3 minor 
criteria; or 
3. 5 minor criteria 
2. 3 minor criteria 
11,14,15 
Table 2. Major and Minor Criteria in the Modified Duke Criteria 
Major Criteria Minor Criteria 
1. Persistently positive blood 
cultures: 
a. ≥2 positive blood 
cultures of blood samples 
drawn >12h apart; or 
b. ≥3 or >4 separate 
cultures of blood with 
first and last samples 
drawn at least 1h apart 
1. Predisposing lesion or IV 
drug use 
2. Evidence of endocardial 
involvement: 
a. Echocardiography 
positive for infective 
endocarditis 
b. New valvular 
regurgitation 
2. Fever >38.0°C 
 3. Vascular phenomena—major 
arterial emboli, septic 
pulmonary infarcts, etc. 
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 4. Immunologic phenomena—
glomerulonephritis, Roth’s 
spots, etc. 
 5. Microbiological evidence—
positive blood cultures not 
meeting major criterion or 
serologic evidence of an 
active infection with an 
organism known to cause 
infective endocarditis 
 6. Echocardiographic findings 
consistent with infective 
endocarditis, but do not meet 
major criteria 
11,14,15 
Probable and proven candidemia were defined according to the criteria set by 
the European Organization for Research and Treatment of Cancer/Invasive Fungal 
Infections Cooperative Group and the National Institute of Allergy and Infectious 
Diseases Mycoses Study Group (EORTC/MSG).12 Time to clearance of candidemia 
was defined as having demonstrated clinical stability and clearing Candida from the 
bloodstream with initiation of maintenance azole therapy.7 Candida endocarditis 
relapse was defined as a new episode of endocarditis due to the same Candida species 
in patients that completed their assigned IV treatment and achieved time to clearance 
of candidemia.13 
Table 3. Definitions for Invasive Candida Infections 
Category Definition 
Proven Candidemia Proof of invasive Candida disease by demonstration of 
Candida-specific elements in diseased tissue of most 
conditions 





The safety profiles of each study regimen were defined according to the 
Patient-Reported Outcomes Version of the Common Terminology Criteria for 
Adverse Events (PRO-CTCAE).17-19 
Table 4. Grades from Common Terminology Criteria for Adverse Events 
Grades Definition 
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
Grade 2 Moderate; minimal, local, or non-invasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living 
Grade 3 Severe or medically significant, but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care activities of daily living 
Grade 4 Life-threatening consequences; urgent indication indicated 
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Chapter 2 – Review of the Literature 
2.1 Introduction 
 A thorough review of the literature was conducted between December 2019 to 
April 2020 using Ovid (Medline, Embase) and Pubmed. Limitations were placed on 
publication year with the use of each database to only include studies from the last 
five years. Publications cited within these articles that did not fall within the time 
limitations were also considered for inclusion in the current analysis. Additionally, 
only articles written and/or translated into English were reviewed. Duplicated 
versions of articles were removed as well. Titles and abstracts were then reviewed to 
determine relevance to our proposed study.  
Articles and cases were included in the current analysis if they met the 
following inclusion criteria: (i) met criteria for proven or probable Candida 
endocarditis, (ii) used an echinocandin-based therapy or a liposomal amphotericin B-
based therapy, and (iii) contained specific information about the outcome of the 
patient(s). Articles and cases were excluded if they (i) received concurrent 
amphotericin B-based and echinocandin-based therapy, (ii) received less than seven 
days of systemic antifungal therapy, or (iii) received surgical intervention only. 
The key terms that were utilized include Candida, endocarditis, amphotericin 
B, micafungin, and echinocandin. Of the 141 articles, 38 were fully reviewed to be 
included within the literature review. The purpose of this literature review is to justify 
the protocol-specific determinations of our study. 
2.2 Overview of Candida Endocarditis 
Fungal endocarditis has an alarmingly high mortality ranging from 30-80%, 
with 53-68% of all cases being Candida species, affecting primarily neutropenic and 
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critically ill, non-neutropenic patients, especially in the nosocomial setting.1-8 
Candida albicans has been identified as being the most common species causing 
candidemia and Candida endocarditis.2,6-8 Prior to 1980, mortality rates for Candida 
endocarditis were reported to be as high as 80%, but through advancements of 
antifungal agents and cardiac surgeries, mortality rates have fallen from 46% to 30% 
within the last decade.3  
Risk factors for the development of Candida endocarditis include not only all 
variables that predispose patients to candidemia—central venous catheters, parenteral 
nutrition, immunosuppression, and prior surgical procedures, but also ones that 
predispose patients to endocarditis, such as intravenous drug use/abuse, prosthetic 
heart valves, valvular abnormalities, transcatheter aortic valve replacement, 
congenital heart abnormalities, previous endocarditis infections, and 
pacemaker/cardiac defibrillator placement.3,4,6,7,9 Out of all of these risk factors, the 
one that poses the highest threat to the development of Candida endocarditis is the 
presence of prosthetic heart valves, which is increasing due to the utilization of 
transcatheter aortic valve replacement and an aging population.3,9 The valves that are 
most affected are typically the aortic valve, followed by the mitral valve.3,5 Based on 
these risk factors, it is predicted that the incidence of Candida endocarditis will 
increase due to the increasing number of elderly patients worldwide, increasing 
number of immunocompromised patients worldwide, and increasing frequency of 
intravascular device placement.5,7 
The clinical presentation of Candida endocarditis is a combination of the signs 
and symptoms associated with candidemia, infectious endocarditis, and 
coagulopathies associated with endocarditis.3,4,6,10 The presence of a new or changing 
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murmur in conjunction with the development of large vegetations with proceeding 
venous thromboembolic events are cardinal findings of Candida endocarditis.3,6,10 
Candida endocarditis should be highly suspected in patients with multiple 
blood cultures positive for Candida species and a major venous thromboembolic 
event; however, it should be noted that not every blood culture will be positive for 
Candida species in the setting of candidemia due to their nature of being slow-
growing, obligate aerobes and the sensitivity for detection being between 50-
75%.3,4,6,7 Additionally, the use of transthoracic echocardiography and/or 
transoesophageal echocardiography is an extremely useful tool in making the 
diagnosis of Candida endocarditis, especially in occult infections, through their ability 
to identify vegetations in the heart.3,6,10 Although both types of echocardiography are 
sufficient evidence for the diagnosis of Candida endocarditis, only the use of 
transoesophageal echocardiography can reasonably exclude the diagnosis of Candida 
endocarditis due to its increased sensitivity and specificity compared to transthoracic 
echocardiography.6,10 
In addition to causing significant fungal infections, C. albicans is known for 
being extremely difficult to treat clinically due to its ability to create biofilms.9,11,12 
These biofilms promote resistance to conventional antifungal therapies, at times, 
leading to clinical failure.9,11-13 Echinocandins and liposomal amphotericin B have 
been identified as the most effective therapy against biofilms, but there has been 
evidence of in vivo development of resistance to these novel antifungals.9,11,12 Azoles, 
which include fluconazole, voriconazole, itraconazole, and posaconazole, were 
initially thought to be a safe and effective therapy in the treatment of Candida 
endocarditis, but data showed that there was a high frequency for failure and relapse, 
resulting in a discontinuation of this treatment standard.3,14 Instead, it was discovered 
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that the most effective use of these medications was after clearance of candidemia and 
subsequent susceptibility testing of the Candida species. 4,6,13,15-17 These medications 
are better served in the step-down therapy of maintaining remission for Candida 
endocarditis because of their fungistatic properties.4,6,13,15-17 
2.3 Current Treatment Guidelines 
Guidelines in the treatment of Candida endocarditis written by both the IDSA 
and European Society of Microbiology and Clinical Infectious Diseases (ESCMID) 
now recommend either an amphotericin B-based or an echinocandin-based therapy 
paired with adjunctive surgery.6,15,18 These recommendations specifically indicate 
either liposomal amphotericin B (3-5 mg/kg daily IV), with or without flucytosine (25 
mg/kg QID PO), or a high-dose echinocandin (caspofungin 150 mg daily IV, 
micafungin 150 mg daily IV, or anidulafungin 200 mg daily IV).15 Antifungal therapy 
should be administered for six to eight weeks, but not less than four weeks.6  
Due to the high mortality rates and poor prognosis of patients that are treated 
with medical treatment alone, fungal endocarditis is considered an indication for 
cardiac surgery and/or valve replacement.5,6,18 However, these guidelines are based on 
evidence provided only by case reports, case series, and clinical experience since 
there are no randomised control trials exploring the most effective treatment strategy 
for this infectious disease.18 Additionally, in cases where cardiac surgery is not an 
option, it is unknown what the optimal primary medical management would be for 
Candida endocarditis.2 This gap in the literature has even been noted by the IDSA, 
acknowledging that their current guidelines are based on low-quality evidence.15 
To date, there have only been observational studies that compare the efficacy 
of an amphotericin B-based therapy to an echinocandin-based therapy for Candida 
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endocarditis.18 Furthermore, there have been no prospective, randomised trials 
comparing the efficacy of an amphotericin B-based therapy to an echinocandin-based 
therapy in the primary treatment of Candida endocarditis.4,18 
A retrospective study conducted by Steinbach et al. found that survival 
likelihood increased with the use of surgery and an antifungal therapy compared to 
antifungal therapy alone.2 However, a prospective study conducted by Baddley et al. 
had data showing that mortality rates were similar between patients receiving either 
surgery and an antifungal therapy (33.3%) or antifungal therapy alone (27.8%) 
(p=0.26).19 Additionally, there have been a number of studies that demonstrate 
treatment success with novel antifungal agents, such as echinocandins, in medical 
therapy alone.4 Surgical management of Candida endocarditis has been linked to a 
high incidence of venous thromboembolic events, such as embolic haemorrhagic or 
ischaemic stroke.4 These complications have been involved in 60% of cases.4 
2.4 Liposomal Amphotericin B 
Prior to the development of further classes of antifungal agents, the standard-
of-care treatment for life-threatening systemic fungal infections caused by species of 
Candida, Aspergillus, and Fusarium has been an amphotericin B-based regimen, 
which is part of a class of antifungals known as polyenes.4,17,18,20 The polyene 
structure of amphotericin B forms complexes with ergosterol, which is an essential 
component of fungal membranes, interrupting the integrity of the cell membrane and 
causing leakage of essential cellular components.20,21 
In instances where adjunctive surgery is not an option, patients would receive 
extended courses of amphotericin B deoxycholate, which has been associated with a 
high mortality rate and amphotericin B-induced nephrotoxicity.2,4,14,17,20 Because of 
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these dose-dependent side effects, a need for formulations that reduce toxicity and 
transport the agent efficiently to specific locations, while still maintaining its 
antifungal effects arose.20 This led to the creation of three additional formulations of 
amphotericin B—liposomes, emulsions, and nanoparticles.20  
Most medical centres are currently using lipid-based amphotericin B 
formulations, more specifically, liposomal amphotericin B, which has a narrower 
toxicity profile when compared to amphotericin B deoxycholate.3,14,20 It has been 
postulated that the reason liposomal amphotericin B is less nephrotoxic is due to the 
drug’s large molecular size and neutral charge, resulting in a more rapid and specific 
distribution to tissues and organs with large reticuloendothelial composition (i.e. liver, 
spleen, lungs, lymphatics), which spares the kidneys, allowing increased deliverance 
of amphotericin B to certain sites of infection.15,21 
Flucytosine is commonly paired with liposomal amphotericin B because it 
provides synergistic fungicidal effects, but if used in high doses or for an extended 
time period, there is a risk for bone marrow toxicity.3,4 Additionally, similar to 
liposomal amphotericin B, flucytosine requires dosage adjustments for patients with 
renal insufficiency.15 
2.5 Clinical Implications of Echinocandins 
With developments in antifungal therapy, a new class of medications, 
echinocandins, created an increase in options for the treatment of Candida 
endocarditis.17,18,22 Echinocandins have shown a decrease in mortality rate compared 
to other antifungal agents when used in the setting of candidemia and other invasive 
Candida infections.23 A panel of experts from the United States of America, Middle 
East region, and Italy have stated in their recommendations that echinocandins are the 
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preferred treatment of proven or probable candidemia, especially in the setting of 
critically ill patients or patients with previous exposure to azoles.1,10,23 Furthermore, 
first-line treatment guidelines of Candida endocarditis in United Kingdom have 
shifted towards high-dose echinocandins instead of liposomal amphotericin B.10,24 
Echinocandins not only have the benefit of being active against a broad 
spectrum of Candida species, but they also have a low tendency to cause drug-drug 
interactions and contain a less severe adverse effect profile.4,9,10,13,14,16,17,22,25 
Echinocandins implement their fungicidal capabilities through their ability to inhibit 
beta-glucan synthesis, thus disrupting the integrity of the fungal cell wall.13,17,18 With 
the disruption of cell wall integrity, intracellular osmotic pressure becomes unstable, 
causing fungal cell lysis.26 The absence of cell walls in mammalian cells is thought to 
be a contributing factor to their attractive safety profile.14,17,26 The improved 
tolerability of these antifungals allows for prolonged, high-dose treatments when 
necessary.4,24  
The first echinocandin approved for the treatment of invasive candidiasis was 
caspofungin in 2003, followed by micafungin and anidulafungin in 2005 and 2006, 
respectively.18,26 Unfortunately, echinocandins cannot be used to treat all types of 
Candida infections because they do not have the ability to reach therapeutic 
concentrations for infections of the eyes, central nervous system, and urine.15 
2.6 Echinocandin Therapy Success in Candidemia 
A prospective, double-blind, randomised control trial was conducted in 
patients with candidemia (n=244) to evaluate non-inferiority between treatment with 
caspofungin (n=109) or amphotericin B (n=115).17 Duration of treatment between the 
two groups was similar (p=0.60) with the caspofungin group having a mean treatment 
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length of 12.1 days (median 11.0 days) and amphotericin B having a mean treatment 
length of 11.7 days (median 10.0 days).17  
In the modified intention-to-treat analysis, it was noted that the 12.7% 
difference in proportion for treatment efficacy amongst non-neutropenic patients was 
without statistical significance between the caspofungin group (73.4%) and the 
amphotericin B group (61.7%) (95.6% CI, -0.7-26.0; p=0.09).17 Additionally, relapse 
rates of candidemia were similar between the caspofungin group (6.4%) and the 
amphotericin B group (7.0%).17 However, when evaluating the successful outcomes 
among patients that met prespecified criteria for evaluation, which were patients 
within the modified intention-to-treat population in conjunction with no concomitant 
antifungal therapies, no protocol violations, an appropriate evaluation at the end of 
treatment, and receipt of study treatment for at least five days, the caspofungin group 
was favoured (80.7%) over the amphotericin B group (64.9%), with a statistically 
significant difference of 15.4% (95.6% CI, 1.1-29.7; p=0.03).17  
Through evaluation of safety and tolerability, it was noted that all drug-related 
adverse events of statistical significance demonstrated favourability of caspofungin.17 
Overall, the caspofungin group had a statistically significant lower proportion of 
clinical events (28.9%, vs 58.4% in the amphotericin B group; p=0.002).17 Patients 
receiving amphotericin B had a higher rate of experiencing chills (26.4%, vs. 5.3% in 
the caspofungin group; p=0.003) and fever (23.2%, vs. 7.0% in the caspofungin 
group; p=0.01).17 Furthermore, amphotericin B had a statistically larger proportion of 
laboratory abnormalities (54.0%, vs. 24.3% in the caspofungin group; p=0.002), 
including elevated blood urea nitrogen (15.8%, vs. 1.9% in the caspofungin group; 
p=0.02), elevated serum creatinine (22.6%, vs. 3.7% in the caspofungin group; 
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p=0.05), and decreased serum potassium (23.4%, vs. 9.9% in the caspofungin group; 
p=0.04).17  
Due to the number of adverse effects experienced by the patients in this study, 
it should be noted that the amphotericin B group had a larger proportion of patients 
that experienced toxic effects (16.5%, vs. 2.8% in the caspofungin group; p=0.03), 
resulting in a change of antifungal therapy.17  
All-cause mortality rate was similar between the caspofungin group (34.2%) 
and the amphotericin B group (30.4%) (p=0.53).17 Similarly, after a post hoc analysis 
was performed to determine mortality secondary to candidemia, the rates were similar 
between the caspofungin group (4.4%) and the amphotericin B group (7.2%) 
(p=0.57).17  
Based on the results from this study, superiority cannot be established between 
caspofungin and amphotericin B in the treatment of invasive candidiasis; instead, it 
can be extrapolated that caspofungin is non-inferior to amphotericin B. However, 
what can be established is that caspofungin had a significantly lower number of 
adverse events compared to amphotericin B.  
Although these results support the caspofungin as an alternative to 
amphotericin B in the treatment of invasive Candida infections, there are two factors 
that limit its generalizability to our study. First, amphotericin B deoxycholate was 
used, which is known to have a more severe adverse effect profile compared to the 
liposomal amphotericin B formulation. Secondly, the use of these antifungals was to 
treat candidemia and not Candida endocarditis, but what must also be considered is 
that data from a prospective cohort (n=187) showed that at least 4.2% of patients with 
candidemia have Candida endocarditis.10 
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2.7 Drawbacks to Echinocandins 
Although echinocandins may seem like a novel class of antifungals that may 
operate as a panacea for invasive fungal infections, it should be noted that like other 
therapies designed to treat infections, resistance may develop. This has been shown 
through a case report involving a patient in France that demonstrated failure in 
treatment with caspofungin for Candida endocarditis.27  
C. glabrata was cultured originally and after susceptibility testing, it was 
determined that the isolates were susceptible to echinocandins, leading to an initial 
treatment with caspofungin.27 After four weeks of treatment with caspofungin, the 
patient developed a second infection, which was isolated and identified as C. 
tropicalis.27 Treatment was continued with caspofungin, but on hospital day ninety-
three, the patient developed a concurrent candidemia with C. albicans.27 
Susceptibility testing of the C. tropicalis and C. albicans demonstrated resistance to 
all echinocandins caused by a missense mutation that changed the coding of the beta-
glucan synthase, rendering the echinocandins ineffective.27 Due to this development, 
the patient had a treatment change from caspofungin to liposomal amphotericin B 
with flucytosine, followed by surgical resection of the vegetation that ultimately led to 
a curative outcome to Candida endocarditis and candidemia.27 This report raises 
concerns for the use of echinocandins because it was previously thought that only C. 
parapsilosis demonstrated slight resistance to echinocandins.4,8,9 
2.8 Animal Studies Supporting Echinocandins 
A prospective, randomised control trial involving rats (n=18) infected with 
Candida endocarditis comprised of C. albicans compared the efficacy between 
caspofungin and liposomal amphotericin B.28 The rats were randomised into three 
treatment groups based on their intervention—caspofungin, liposomal amphotericin 
22 
 
B, and placebo.28 Fungal density of the extracted vegetations, the primary outcome, 
was measured based on average absorbance of blood cultures from the rats and 
showed a significant statistical difference (p<0.05) between the rats that were treated 
with an antifungal, either caspofungin or liposomal amphotericin B, and the rats that 
received a placebo.28  
While the rats that were treated with an antifungal showed no statistically 
significant differences, the rats treated with placebo only showed a statistically lower 
absorbance, which was similar to the positive control: 0.878 (placebo) versus 0.865 
(positive control).28 Conversely, the rats treated with caspofungin had an average 
absorbance (0.230), which was similar to the rats treated with liposomal amphotericin 
B (0.251).28  
The lack of statistically significant difference in the two antifungal treatment 
groups lend to the hypothesis that an echinocandin would be non-inferior to liposomal 
amphotericin B in the treatment of Candida endocarditis. Furthermore, histological 
comparison of the fibrinous vegetations were characterized between the rats treated 
with caspofungin and the rats treated with liposomal amphotericin B.28 While both 
antifungal treatment groups had reduction in colony size, the caspofungin treatment 
group also showed a disruption in the structural integrity of the hyphae, indicating 
damage to the membranes of the remaining C. albicans.28 Unlike the caspofungin 
treatment group, the liposomal amphotericin B treatment group did not cause any 
distortions to the hyphae, which shows that liposomal amphotericin B only affects the 
membrane permeability of the Candida species.28 
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2.9 Caspofungin, Micafungin, and Anidulafungin 
Caspofungin has the highest number of indications of the three echinocandins, 
closely followed by micafungin.23 While both caspofungin and micafungin are 
approved for treatment of candidemia or invasive candidiasis in both non-neutropenic 
and neutropenic adult and paediatric patients, caspofungin has additional indications 
through its use in salvage therapy for invasive aspergillosis and empirical treatment of 
febrile neutropenia.23  
Although caspofungin has been the echinocandin most used in the treatment of 
Candida endocarditis publications, it is unknown which of the three echinocandins is 
preferred because there is no evidence directly comparing superiority over one 
another.3,10,23 The Clinical and Laboratory Standards Institute (CLSI) M27-A3 and the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) were 
developed to establish standardized methodologies in the testing of susceptibility of 
fungi against available antifungal agents.15 Based on minimum inhibitory 
concentrations, pharmacokinetic data, pharmacodynamic data, and animal data, 
interpretative breakpoints for susceptibility were established for several antifungal 
agents against, in decreasing order of incidence, five of the most common Candida 
species—C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei.15 
Based on this current data, it is assumed that the three different echinocandins are 
equivalent in their fungicidal effects.3,10  
Table 5. Clinical Breakpoints for Echinocandins Against Common Candida Species 
Candida Species Echinocandin Susceptibility Intermediate Resistance 































































Additionally, there have been no studies that directly observe and analyse the 
differences in several pharmacokinetic and pharmacodynamic factors.23 However, 
there has been one retrospective study (n=66) showing no statistically significant 
differences in mortality rate when treating candidemia or invasive candidiasis with 
either micafungin (29.1%) or caspofungin (45.9%).8  
While caspofungin has been the echinocandin most often used in case reports, 
there is some evidence that micafungin would be a more appropriate alternative. 
Micafungin has similar indications in its use of candidemia and Candida endocarditis 
in relation to caspofungin, but it has the added benefit of being indicated in 
newborns.23 Additionally, unlike caspofungin, micafungin does not require a loading 
dose or dosage adjustments for patients with moderate to severe hepatic insufficiency, 
making it an attractive alternative for patients with multiple comorbidities.14,15 
Additionally, compared to micafungin, caspofungin has been shown to have the most 
drug-drug interactions of all echinocandins, specifically affecting the pharmacokinetic 
profiles of cyclosporine, tacrolimus, and rifampin.26 Unfortunately, over the last two 
decades, caspofungin and micafungin have been used as both first-line treatment and 
prophylaxis of candidemia and subsequent infections, leading to the breeding of 
echinocandin-resistant Candida species.8,27 
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2.10 Micafungin in Candidemia 
A prospective, double-blind, randomised control trial (n=531) was conducted 
to determine if micafungin (n=264) would be non-inferior to liposomal amphotericin 
B (n=267) in the setting of candidemia.14 The primary outcome that was being 
investigated between all populations was the response rate of overall treatment 
success, which was quantified by both a clinical and mycological response at the 
conclusion of antifungal therapy.14  
The populations of these groups were further separated into three analysis 
populations: per-protocol population (n=202 in the micafungin group, vs. n=190 in 
the liposomal amphotericin B group), intention-to-treat population (n=264 in the 
micafungin group, vs. n=267 in the liposomal amphotericin B group), and the 
modified intention-to-treat population (n=247 in the micafungin group, vs. n=247 in 
the liposomal amphotericin B group).14 This specific study had chosen to include 
results from both the intention-to-treat and the modified intention-to-treat populations 
due to them both being identified as critical information to draw a conclusion of non-
inferiority.14 
When comparing the results from the intention-to-treat population, defined as 
those that received at least one dose of the study drug, there was no statistically 
significant difference in treatment success when comparing micafungin (71.6%) to 
liposomal amphotericin B (68.2%).14 Additionally, after stratification of neutropenic 
status, the difference between non-neutropenic patients was 3.9% (CI 95%, -3.9-
11.6).14  
The results of the modified intention-to-treat population, which were those 
that received at least one dose of the study drug and had confirmed Candida infection, 
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demonstrated no statistically significant difference in treatment success (4.5%) 
between micafungin (74.1%) and liposomal amphotericin B (69.6%) (CI 95%, -3.5-
12.4).14 Furthermore, stratification by neutropenic status showed a difference of 4.9% 
between non-neutropenic patients, which was still not statistically significant (CI 
95%, -3.0-12.8).14  
Finally, the results from the per-protocol population, which was the primary 
efficacy population, showed similar overall treatment success between the micafungin 
group (89.6%) and the liposomal amphotericin B group (89.5%), with a difference in 
proportions of 0.1% (95% CI, -5.9-6.2).14 After stratification by neutropenic status, 
the difference in proportion between non-neutropenic patients was 0.7% (95% CI, -
5.3-6.7).14 
Regarding candidemia, similar rates of success were observed between the 
micafungin group (90.6%) and the liposomal amphotericin B group (90.8%).14 
Mortality rates were similar over the entirety of the study of the intention-to-treat 
population of micafungin (40%) and liposomal amphotericin B (40%).14 When 
examining if the cause of death was directly related to the fungal infection, it was 
noted that, again, the micafungin group (13%) was similar in comparison to the 
liposomal amphotericin B group (9%) (p=0.22).14 When specifically looking at 
Candida endocarditis, there was a difference in treatment success, but without 
statistical significance, between the micafungin group (1/1, 100%) and the liposomal 
amphotericin B group (3/4, 75.0%).14 More patients would need to be evaluated in 




When comparing the treatment-related adverse effects, it was noted that, 
overall, there was not a significant difference in adverse effects between micafungin 
(43.2%) and liposomal amphotericin B (50.9%) (p=0.082).14 Additionally, micafungin 
did not demonstrate any statistically significant differences in serious adverse effects 
(4.2%, vs. 7.5% in liposomal amphotericin B; p=0.138) or treatment discontinuation 
(4.9%, vs. 9.0% in liposomal amphotericin B; p=0.087).14 However, with micafungin, 
there was a statistically significant lower rate of rigors (0.8%, vs. 6.4% with liposomal 
amphotericin B group; p=0.0006), increased blood creatinine (1.9%, vs. 6.4% with 
liposomal amphotericin B group; p=0.015), back pain (0.4%, vs. 4.5% with liposomal 
amphotericin B group; p=0.003), and infusion-related reactions (17.0%, vs. 28.8% 
with liposomal amphotericin B group; p=0.001).14  
Based on the results of treatment success between the three analysis 
populations, it has been shown that micafungin is non-inferior to liposomal 
amphotericin B in the primary treatment of candidemia and invasive candidiasis. 
Inferences based on these two antifungal therapies cannot be made in reference to 
Candida endocarditis due to the limitation of having only five patients within the 
study.14 However, although non-inferior to liposomal amphotericin B, micafungin 
showed superiority in safety profile compared to liposomal amphotericin B, 
specifically in renal function and infusion-related events. This data related to safety 
profile bridges the gap in literature from the study comparing caspofungin and 
amphotericin B deoxycholate because there is now evidence comparing 
echinocandins and liposomal amphotericin B. 
2.11 Case Reports Using Liposomal Amphotericin B in Candida Endocarditis 
While conducting our literature review, we summarized recent case reports 
that used a liposomal amphotericin B-based treatment regimen in the setting of 
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Candida endocarditis. All included cases had a diagnosis of Candida endocarditis 
through multiple, positive blood cultures and vegetations visualized either by 
transthoracic and/or transoesophageal echocardiography. All cases reported successful 
treatment of Candida endocarditis with or without use of adjunctive surgery, which 
should be noted as a potential bias that the researchers have identified. Table 5 
contains a brief summary of information regarding each case report. 





Therapy Surgery Outcome 
Bauer7 64/M C. tropicalis L-AMB 5 mg/kg/d + 
5-FU 25 mg/kg QID 
for 26 days 
Dose reduction of L-
AMB to 3 mg/kg for 







Gardiner29 56/M C. 
parapsilosis 
Ani 200 mg for 4 
days 
L-AMB 5 mg/kg/d + 
5-FU 500 mg QID for 
17 days 
Discontinuation of L-
AMB due to renal 
toxicity 
Ani 200 mg + fluc 
800 mg for 6 weeks 
















56/M C. krusei AmB 50 mg/d for 4 
weeks 
























5-FU – Flucytosine; AmB – Amphotericin Deoxycholate; Ani – Anidulafungin; AV 
– Aortic Valve; Cr – Creatinine; Fluc – Fluconazole; L-AMB – Liposomal 
Amphotericin B; MV – Mitral Valve; QID – quater in die 
2.12 Liposomal Amphotericin B with Flucytosine in Candida Endocarditis 
In a recent retrospective study (n=46) of Candida endocarditis, thirty-one 
patients (67%) received antifungal therapy alone.32 Of the thirty-one patients, 
seventeen (55%) received liposomal amphotericin B with flucytosine and fourteen 
(45%) received an echinocandin, either caspofungin or anidulafungin.32 From the 
subset of patients that were receiving liposomal amphotericin B with flucytosine, ten 
developed renal insufficiency, leading to its discontinuation in three patients.32 
Although more patients developed renal injury in this treatment group, it was noted 
through univariate analysis that compared to all other induction antifungal therapies, 
liposomal amphotericin B with or without flucytosine (26% survival without 
flucytosine; 33% survival with flucytosine) was associated with a lower six-month 
mortality rate.32 During review of six-month survival rate by multivariate analysis, it 
was noted that patients receiving liposomal amphotericin B-based monotherapy had a 
higher survival rate than those receiving an echinocandin-based monotherapy (95% 
CI, 1.03-838.10; aOR 13.52).32 Through the evidence provided by this study, the data 
supports the recommendation of having the primary pharmacological therapy for 
Candida endocarditis consisting of a liposomal amphotericin B-based therapy, more 
specifically, one that includes the use of flucytosine. 
A meta-analysis totalling 879 cases of reported Candida endocarditis between 
1966-2002 reviewed 418 reports.2 Through the authors’ inclusion criteria of definitive 
Candida endocarditis, 105 reports containing a total of 163 patients were reviewed.2 
In order to reflect current medical practices, cases after 1980 (n=92), which was the 
decade where echocardiography technology emerged, were summarized with greater 
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detail by including location of cardiac valve involvement, type of infected valve, and 
specific treatment details.2  
These cases were divided based on pharmacological and/or surgical 
treatment—medical antifungal monotherapy (n=15), medical antifungal combination 
therapy (n=19), and medical antifungal therapy with adjunctive surgery (n=58).2 
Within the medical antifungal monotherapy group, 53.3% (8/15) had reported 
successful outcomes.2 The most commonly used antifungal was amphotericin B 
(53.3%), which had the second highest reported successful outcome (75.0%).2 The 
second most commonly used antifungal was fluconazole (40.0%), which resulted in a 
successful outcome of 16.7%.2 Flucytosine monotherapy had the highest reported 
treatment success (100%); however, it should be noted that only one patient was 
treated with flucytosine monotherapy.2  
Within the medical antifungal combination therapy group, 63.2% (12/19) had 
successful reported outcomes.2 The most commonly used medical antifungal 
combination therapy was amphotericin B with flucytosine (73.7%), which had the 
third highest reported successful outcome (63.2%), following amphotericin B with 
fluconazole (66.7%) and amphotericin B with rifampin and flucytosine (100%).2 
However, similar to the monotherapy group, it should be noted that the number of 
patients treated with amphotericin B with fluconazole and amphotericin B with 
rifampin and flucytosine were comprised of three and one patients, respectively.2  
With the use of meta-regression analysis techniques and using mortality as the 
outcome, mortality was highly associated in patients that were treated with antifungal 
monotherapy (95% CI, 0.39-5.81; Prevalence Odds Ratio (POR) 1.49).2 The findings 
from this meta-analysis suggest that when treating Candida endocarditis with medical 
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therapy alone, combination therapy is preferred to monotherapy alone.2,4 Additionally, 
although the medical antifungal combination therapy of amphotericin B with 
flucytosine had the third highest rate of successful reported outcomes, the two 
medical antifungal combination therapies with higher reported successful outcomes 
were not sufficiently powered, making them lack statistical significance. 
While this meta-analysis shows a higher rate of treatment success with 
amphotericin B-based combination therapy, it must be noted that this study did not 
include the use of any echinocandin-based therapy. 
2.13 Case Reports Using Echinocandins in Candida Endocarditis 
During our review of recent literature, we summarize case reports that use 
echinocandins in the setting of Candida endocarditis. The case of the 69-year-old 
male was given a clinical diagnosis of Candida endocarditis via two major criteria 
(persistently positive blood cultures and evidence of endocardial involvement) 
because the transoesophageal echocardiogram only revealed fibrin stranding.13 This 
patient’s clinical diagnosis was further supported by the presence of three minor 
criteria (fever above 38.0°C, predisposing lesion, and echocardiographic findings 
consistent with infective endocarditis, but do not meet major criteria).13 
All other cases had a diagnosis of Candida endocarditis through multiple, 
positive blood cultures and transthoracic and/or transoesophageal echocardiography. 
The majority of case reports resulted in treatment success of Candida endocarditis 
with and without the use of adjunctive surgery, which should be noted as a potential 
bias that the researchers have identified. More details are provided on these cases in 
Table 7. 







Therapy Surgery Outcome 
Morioka9 80/M C. 
parapsilosis 
L-AMB 3 mg/kg/d for 
8 days 
Discontinuation of L-
AMB due to rising Cr 
Mica 150 mg/d + fluc 











Ahuja13 69/M C. 
parapsilosis 
L-AMB 5 mg/kg/d 
Discontinuation of L-
AMB due to rising 
creatinine 
Mica 150 mg + fluc 






Ahuja13 45/M C. 
parapsilosis 
Mica 150 mg + fluc 6 
mg/kg for 2 weeks 
L-AMB 5 mg/kg/d + 5-
FU 2500 mg Q6H + 
fluc 400 mg/d for 1 
week 
Discontinuation of L-
AMB due to rising Cr 
Mica 150 mg/d + fluc 
400 mg/d + 5-FU 2500 
mg/d followed by an 
increase in 5-FU to 







Kubota33 31/F C. albicans L-AMB 200 mg/d for 4 
days 
Discontinuation of L-
AMB due to rising Cr 
L-AMB 200 mg/d for 
14 days 
Discontinuation of L-
AMB due to rising Cr 
Mica 150 mg/d + fluc 















86/M C. tropicalis Caspo 70mg for 1 day 
Caspo 50mg for 10 
days 





















70/F C. glabrata Caspo 70mg for 2 days - Decease
d day 31 
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Caspo 100mg + 5-FU 
37.5mg BID 
Discontinuation of 
caspo due to 
hepatotoxicity 




69/F C. albicans Ani 200mg for 1 day 















5-FU – Flucytosine; Ani – Anidulafungin; Caspo – Caspofungin; Cr – Creatinine; 
Fluc – Fluconazole; L-AMB – Liposomal Amphotericin B; Mica – Micafungin; PM 
– Pacemaker; PV – Pulmonary Valve; TV – Tricuspid Valve 
 
2.14 Review of Studies to Identify Possible Confounding Variables 
Throughout the extensive literature review, it has been noted that there are 
several confounding variables that have influenced the generalizability of conducting 
this study. Most of these confounding variables will be attempted to be curbed 
through the use of a highly specific exclusion and inclusion criteria, as well as 
stratification of subgroups during statistical analysis.  
Although C. albicans has historically been identified as the species of Candida 
to most often cause Candida endocarditis and candidemia, the prominent global use of 
azoles for prophylaxis and treatment has been associated with the epidemiological 
shift to other Candida species.8,16 Local epidemiology describing the species of 
Candida need to be considered for empiric treatment of invasive Candida 
infections.8,16 This will be done by stratification based on recruitment site. 
Mortality is directly correlated with delays in both the identification of 
Candida endocarditis and choice of the most efficacious antifungal agent.6,16 
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Identifying the infectious source is extremely important in the management of 
Candida endocarditis and candidemia—whenever possible, infected medical devices 
need to be promptly removed and abscesses need to be drained.10,14,16 Failure to 
quickly identify and address these infectious sources is correlated with increased 
mortality while swift intervention to achieve source control to reduce fungal inoculum 
is correlated with improved clinical outcomes.6,10,16 
Only patients diagnosed with proven and probable Candida endocarditis will 
be included in the study to avoid bias related to the pathogenic characteristics specific 
to other fungal pathogens.5 After identification of patients with proven Candida 
endocarditis, comorbid conditions that have been acknowledged as independent 
predictors of all-cause mortality will need to be taken into account. Acute heart failure 
has been recognised as an independent predictor of all-cause mortality, as well as 
glycaemic control in diabetic patients needing to be optimized.5,16 Finally, if clinically 
possible, the use of immunosuppressive and/or antibacterial therapies should be 
decreased or stopped.16 
2.15 Review of Relevant Methodology 
 To our knowledge, all published clinical trials investigating the efficacy and 
safety of an amphotericin B-based regimen or an echinocandin-based therapy have 
been through the use of randomised control trials or retrospective 
analyses.2,5,8,14,17,18,22,28,32 Based on our goal of determining non-inferiority, our study 
was designed as a randomised control trial to allow for control of patients and 
treatment options. 
Patients 16 years of age or older were eligible for recruitment into the study.14 
Non-neutropenic patients receiving an azole-based systemic antifungal prophylaxis 
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for three or more days within the last seven days were ineligible for recruitment into 
the study.14 Neutropenic patients, defined as having an absolute neutrophil count less 
than 500 cells per microlitre, receiving antifungal prophylaxis were eligible for 
recruitment into the study.14 
The modified Duke Criteria was developed in aiding the diagnosis of infective 
endocarditis; however, it was created through data from bacterial endocarditis.4 There 
are currently no diagnostic criteria that are specific to the identification of fungal 
endocarditis.4 Utilization testing for the Mannan antigen and the anti-mannan 
antibodies is another useful diagnostic tool due to the combined sensitivity of 83% 
and specificity of 86% for Candida endocarditis.4,6 The downfall to this diagnostic test 
is that empiric treatment with antifungals can lower the levels of the Mannan antigen 
and anti-mannan antibodies.4 Based on this information, the modified Duke criteria, 
positive candidemia cultures, and utilization of the transthoracic and/or 
transoesophageal echocardiogram will be used to determine Candida endocarditis 
diagnosis. 
While on either the echinocandin-based or liposomal amphotericin B-based 
therapy, clinical success has been documented in patients that received treatments for 
six to eight weeks.6 In the setting of Candida endocarditis, it would be considered 
inappropriate to treat with either medical therapy for less than four weeks.6 
In order to determine cessation of candidemia, daily blood cultures must be 
drawn until sterilisation of the blood is noted.6,10 Upon clearance of candidemia, the 
general consensus is to continue antifungal treatment for an additional two weeks, but 




 The existing evidence provided by a series of case studies, meta-analyses, and 
randomised control trials have demonstrated promise in the use of micafungin as a 
non-inferior alternative to liposomal amphotericin B with flucytosine for the treatment 
of Candida endocarditis. With micafungin providing several instances of successful 
treatment of Candida endocarditis, as well as a more tolerated side effect profile, this 
choice of echinocandin is the next logical choice for further investigation in the 
treatment of this deadly disease. Comparison of all-cause mortality from initiation of 
the assigned study medication to the end of treatment as the primary outcome, 
together with measuring time to clearance of candidemia, assessing safety profile 
through adverse side effects, and identifying relapse of Candida endocarditis after 
initiation of step-down therapy as secondary outcomes will provide the setting for this 
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Chapter 3 – Study Methods 
3.1 Study Design 
 We will be performing a prospective, randomized, double-blind, international, 
multicentre, non-inferiority clinical trial comparing liposomal amphotericin B and 
flucytosine versus micafungin for the primary treatment of Candida endocarditis. 
Enrollment will be conducted between January 2021 to June 2022 based on 
convenience sampling. Study participants will be randomized to the control group 
(liposomal amphotericin B with flucytosine) or intervention group (micafungin) using 
a third-party, computerized random number generator. Data collection will be 
conducted between July 2022 to December 2022. 
3.2 Study Population and Sampling 
 Patients 16 years or older will be eligible if they are considered to meet the 
criteria of infective endocarditis set by the modified Duke criteria,1 as well as criteria 
for probable or proven candidemia.2 Key inclusion and exclusion criteria will be 
further discussed in the following sections, with full criteria being found in the 
appendix. Only patients that meet all inclusion criteria and none of the exclusion 
criteria will be eligible to participate in the study, which will include a preliminary 
screening visit that will include, but not be limited to, physical examinations and 
blood samples. Due to the rarity of Candida endocarditis, convenience sampling will 
be utilized with a 1:1 allocation to assign subjects to receive either amphotericin B 
with flucytosine or micafungin.  
3.3 Inclusion Criteria 
 The following inclusion criteria will be disseminated to participating sites to 
screen potential study participants: patients 16 years or older that meet that pathologic 
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criteria and clinical criteria of definite infective endocarditis.1 After initial screening, 
participants will be categorized into criteria for proven, probable, and possible 
Candida endocarditis.2 Once complete, only the participants that have met the criteria 
for proven or probable Candida endocarditis will be included into the study. In 
addition to meeting these key inclusion criteria, patients will also be screened via 
blood sampling to determine renal function based on creatinine levels. A full list of 
inclusion criteria can be found in the appendix.  
3.4 Exclusion Criteria 
 Key exclusion criteria will be distributed to participating sites. If either of the 
key exclusion criteria are met, the patient will be deemed ineligible for recruitment 
due to the contraindications of liposomal amphotericin B with flucytosine 
administration. These key exclusion criteria included patients with moderate-to-severe 
renal insufficiency, defined as a calculated creatinine clearance <50 mL/min.3 
Additional exclusion criteria includes known hypersensitivity or allergy history to the 
proposed study medications and/or their adjuvant components,3 acute heart failure,4 
patients with poor glycaemic control,5 and body weight less than forty kilograms.6 
Antifungal prophylaxis will be considered a relative exclusion criterion—non-
neutropenic patients on systemic antifungal prophylaxis for three or more days within 
the last seven days will be excluded, but neutropenic patients on antifungal 
prophylaxis will be allowed to be included.6 A full list of exclusion criteria can be 
found in the appendix.  
3.5 Subject Protection and Confidentiality 
 This study will be reviewed by the Institutional Review Board (IRB) or 
independent ethics committees at each of the participating sites. All eligible patients 
will be given information verbally by study personnel. If interested, these patients will 
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then be given a study brochure that will detail all pertinent information to be enrolled 
in the study. Once the patient decides to partake in the study, he or she will be 
required to give verbal consent, as well as written consent by signing an IRB-
approved consent form. This consent form will outline the purpose of the study, the 
two treatment groups, randomization procedures, requirements of the patient, timeline 
of the study, and possible treatment-related adverse effects. If the patient wishes to 
withdraw from the study at any point in time, the IRB-approved consent form will 
detail how to formally withdraw from the study. The study brochure and IRB-
approved consent form will be included in the appendix. 
 In order to maintain confidentiality of patients, the research conducted in this 
study will adhere to policies and regulations set forth by the Health Insurance 
Probability and Accountability Act (HIPAA). All identifying patient information will 
be kept strictly confidential with IRB-approved patient database. Additionally, all 
study personnel will be required to undergo HIPAA training and certification. 
Documentation of this training and certification will be kept by the principal 
investigators.  
3.6 Recruitment 
 In order to participate in the study, interested healthcare facilities will be 
required to have their governing bodies approve of the study protocols and any 
amendments that may be made. Once recruited, the participating study sites will 
facilitate the enrolment of patients to obtain the required sample size by providing the 
eligible, interested patients with further study information, including the study 
brochure. In the event that the patient is unable to make medical decisions for himself 
or herself, consent for enrolment into the study must be obtained by the legally 
authorized representative of the patient. 
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3.7 Study Variables and Measures 
 The intervention of this study will be the administration of micafungin at 
150mg IV daily with a placebo PO QID to maintain blinding. The control for this 
study will be the standard of care, which is liposomal amphotericin B 4mg/kg IV 
daily with flucytosine 25 mg/kg PO QID.7 Both interventions will be given for a 
minimum of six weeks, but no longer than eight weeks.7 
 The primary dependent variable will be an all-cause mortality from the day of 
assigned study drug regimen to day fifty-six. Day fifty-six was chosen due to the 
maximum therapy duration for Candida endocarditis being eight weeks.7 
 Secondary dependent variables will include time to clearance of candidemia, 
assessment of adverse effects, and determination for the incidence of relapse of 
Candida endocarditis after the initiation of step-down maintenance therapy. After 
identification of the Candida species, susceptibility testing will be conducted and the 
appropriate step-down therapy (PO voriconazole 200-300 mg (3-4 mg/kg) BID, long-
acting posaconazole 300 mg daily, or fluconazole 400-800 mg (6-12 mg/kg) daily) 
will be administered.7 
3.8 Blinding of Intervention 
 All personnel involved in the study were blinded to treatment allocation, 
except for two research pharmacists at each participating study site. One research 
pharmacist would be responsible for the preparation and dosing of medications, which 
would be blinded during administration via opaque coverings on medication 
administration sets. If placed in the intervention group (micafungin), the patient 
would also be given a placebo at the frequency of flucytosine administration in the 
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control group. The second research pharmacist would be responsible for reviewing 
drug accountability records.  
3.9 Blinding of Outcome 
 The study participants will be blinded to the primary and secondary outcomes 
while being treated in the inpatient setting. The researchers will be blinded to the 
primary or secondary outcomes while treating the patients in the inpatient setting. 
3.10 Assignment of Intervention 
Patients will be randomly assigned to either receive 150mg of micafungin IV 
daily with a placebo PO QID or 4mg/kg of liposomal amphotericin B IV daily with 
25mg/kg of flucytosine PO QID for 8 weeks. Randomisation will be conducted in a 
1:1 ratio and stratification will be conducted based on treatment site, as well as 
baseline neutropenic status. In addition, a third-party computer program will be used 
to generate randomisation to ensure true random probability for treatment allocation 
at each site. This use of the third-party computer program will maintain the integrity 
of our results. 
3.11 Adherence 
Adherence to the allocated treatment would be maintained through research 
personnel. Study participants would not be expected to administer the medication 
themselves; therefore, interventions will only be administered within the inpatient 
setting of the study participants’ hospitalisation. Supervision of adherence will be 
maintained through the use of study nurses at the study sites through their 
documentation of study medication administration. Additionally, prior to the first 




3.12 Monitoring of Adverse Events 
Study participants will be informed to notify investigators of any adverse 
effects they are experiencing. Investigators will record the reported adverse effects on 
a standardised form and will categorise these adverse effects based on PRO-CTCAE. 
In addition to recording these reported adverse effects, study participants will also 
have daily morning assessment of their serum chemistry laboratories, such as 
complete blood count, complete metabolic panel, electrolyte panels, etc. and 
categorised based on the PRO-CTCAE. 
3.13 Data Collection 
 All necessary data of the study participants will be recorded via the patient’s 
online medical records, as well as a separate form in order to maintain accumulation 
of mandatory information for statistical analysis of the primary and secondary 
outcomes. 
Assessment of probable and proven Candida endocarditis will be done at 
baseline, weekly during the treatment phase, and at the end of therapy using the 
modified Duke Criteria. Assessment of probable and proven candidemia will be done 
at baseline, weekly during the treatment phase, and at the end of therapy using the 
EORTC/MSG. 
 The primary endpoint is all-cause mortality at day fifty-six and based on 
whether the study participant had expired from any cause in the hospital. The 
secondary endpoint of measuring time to clearance of candidemia will be determined 
through two sets of negative blood cultures. Additionally, drug-related adverse effects 
will be documented based on categorisation of PRO-CTCAE throughout the entirety 
of the treatment phase. Finally, identification of relapse will be assessed for patients 
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that experience treatment success through the treatment phase but showed re-
emergence of the same Candida isolates after completion of IV treatment. 
3.14 Sample Size Calculation 
We based our sample size calculation on all-cause mortality published by an 
observational cohort study that examined Candida endocarditis with a specific focus 
on therapy modalities.8 However, due to the scarcity of data in regard to micafungin 
success specifically in Candida endocarditis, the rate of success in Candida 
endocarditis is from echinocandins as a class instead of individually.8 In order to 
calculate sample size, a program called Sealed Envelope Limited 2012 – Power 
Calculator for Binary Outcome Non-Inferiority Trials was used. 
Assuming liposomal amphotericin B with flucytosine has a successful 
response rate of 55% (45% mortality rate) and micafungin has a successful response 
rate of 64% (36% mortality rate), (α=0.05, β=0.2, δ=0.10) it was determined that a 
total of 82 patients per treatment group were needed to determine non-inferiority.6,9-11 
This would result in a need for roughly 164 patients in the study; however, we are 
planning to enrol a total of 223 patients through the assumption of the need to exclude 
36% of patients from the per-protocol set.6 
3.15 Statistical Analysis 
Although this study will be conducting statistical analyses of the primary and 
secondary endpoints of the per-protocol population, the intention-to-treat (ITT) 
population and the modified intention-to-treat population (mITT) will be of most 
interest and significance. The ITT population, the primary efficacy population, will 
include all patients that were enrolled, randomised, and received at least one dose of 
either experimental treatment therapy.3 The primary efficacy endpoint will be all-
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cause mortality from the first dose of the assigned therapy to day fifty-six in the ITT 
population because this population would best represent the patients receiving 
antifungal treatment in a real-wold setting.3,6 Additionally, the mITT population will 
be essential in drawing the conclusion of non-inferiority because this population will 
consist of the number of study participants that were determined to have probable or 
proven candidemia, based on the EORTC/MSG.6 
Continuous variables will be presented as the median and interquartile range 
and will be compared using the Mann-Whitney test. Categorical variables will be 
presented as numbers and percentages that will compared using either the Chi-square 
test or Fisher’s exact test. 
3.16 Timeline and Resources 
 Our proposed study will take approximately two years, which will include 
subject recruitment, baseline assessment, and follow-up period. We anticipate 
beginning our study in January 2021 with subject recruitment, which will extend to 
June 2022, totalling eighteen months (months 0-18). The proposed timespan for 
recruitment will allow for our study to maximize recruitment and develop a study 
population that will hopefully be generalisable to the interested population. This will 
allow for six months of completing the assigned regimen, which will be administered 
for no less than four weeks, but no more than eight weeks (months 18-20).7 If 
clearance of candidemia is achieved, the assigned antifungal therapy will continue for 
an additional two weeks per standard of care (month 20).12 In order to abide by 
recommendations for the treatment of Candida endocarditis, patients will be given an 
appropriate step-down therapy.7 Follow-up after step-down therapy will determine 




This period of twenty-four months will not include time to IRB approval or 
the proposed data analysis. It is anticipated that approval for this study by the IRB 
will take approximately four months. Additionally, we predict that data analysis will 
take no more than five months.  
The required resources for this study will largely be covered by the recruited 
study sites. The only foreseeable additional charge that will affect these institutions is 
recruitment of research assistants. The need for additional research assistants will be 
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Chapter 4 – Conclusion 
 Candida endocarditis is a rare and deadly disease.1 It has been shown to be an 
issue for both non-neutropenic and neutropenic patients.2-4 Research regarding this 
infection is scarce, with the only data supporting the current standard of care being 
from five decades of successful treatment in case reports.4,5 Furthermore, the evidence 
to show a possible alternative to the standard of care is from successful treatments in 
case reports as well. Gaps in knowledge around Candida endocarditis will continue if 
there are no prospective randomized control trials conducted. This proposed study 
aims to determine if the recommendations for the treatment of Candida endocarditis 
can be given evidence in a controlled study. If effective, recommendations by the 
IDSA and ESCMID will finally be able to support their strong recommendations with 
high-quality evidence instead of low-quality evidence.4,6,7 
4.1 Study Advantages 
 If this study is approved, there are a plethora of benefits that will be provided 
by the gathered data. To date, this will be the first prospective randomised control trial 
to compare the standard of care for Candida endocarditis to a novel antifungal 
therapy. By providing evidence of non-inferiority, the primary outcome, and taking 
advantage of existing data of echinocandins, specifically micafungin, an alternative 
treatment can be provided to patients. Additionally, the existing literature today has 
primarily observed the use of caspofungin on Candida endocarditis. This study will 
broaden our knowledge on one of the lesser used echinocandins, in this specific 
context, micafungin.  
 Based on the results of the secondary outcomes, several benefits could be 
drawn from that data. Through analysis of the adverse effects, combined with the 
existing data from the literature review, we will be able to determine if micafungin is 
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not only an alternative to Candida endocarditis based on efficacy, but also if 
micafungin is safer and/or more tolerable for patients. Through the isolation of 
Candida species, we will also be able to characterise epidemiological differences 
between Candida species in different areas of the world. This will provide more 
information for practitioners so that empirical treatment can be more evidence-based. 
4.2 Study Disadvantages 
 Unfortunately, like all other studies, our study will have its disadvantages. 
Despite having a prolonged period for recruitment, it is assumed that the majority of 
the patients will be non-neutropenic because Candida infections are showing growing 
incidence through the increased use of illicit intravenous drugs.2-4 Similar to most 
mycological studies, we attempt to reduce this generalizability bias through 
stratification of study participants into groups of neutropenic patients and non-
neutropenic patients. Additionally, we cannot generalize our results to patients with 
renal insufficiency, acute heart failure, underweight patients, or patients with poor 
glycaemic control because they were excluded through each of these factors being 
confounding and independent to mortality.  
Furthermore, this study will not give any information or data regarding 
adjunctive surgery, such as optimal timing and necessity of the surgery. This study 
will only be examining pharmacological therapy. Finally, our study will be 
monitoring the efficacy of micafungin monotherapy. There have been studies, not 
involving echinocandins however, demonstrating superiority of combination 
antifungal therapy, but there is not enough information nor published case reports to 




4.3 Clinical and/or Public Health Significance 
 As incidence of Candida endocarditis increases, there is a definitive need for 
evidence-based medicine to guide optimal management of this deadly infection. 
Historically, amphotericin B deoxycholate has been used, but was limited in its use 
through significant renal toxicity.8 Although there has been a development of a lesser 
nephrotoxic formulation, liposomal amphotericin B, it still has a high propensity to 
cause damage to the kidneys and is extremely expensive.8 The data from this study 
would have the potential of being a landmark study through evidence of a less 
expensive, more tolerable, and possibly non-inferior alternative in treating this deadly 
disease—echinocandins. 
4.4 Future Studies 
 Depending on the results from our proposed trial, there are a series of logical 
steps that can be taken in the treatment of this mycological heart infection. If non-
inferiority is shown with micafungin, future studies can observe the efficacy of the 
other lesser used echinocandin, anidulafungin. Furthermore, since it was determined 
that combination therapy is superior to monotherapy in the pharmacological treatment 
of Candida endocarditis, future studies could investigate what antifungal drugs could 
be best combined with echinocandins. 
Additionally, based on the literature review performed, future studies could 
evaluate adjunctive surgery for Candida endocarditis. One future study that should be 
addressed would be the most appropriate time for adjunctive surgery after the 
initiation of pharmacological therapy. There is no recommendation regarding when 
adjunctive surgery should take place after initiation of antifungal therapy. Conversely, 
a future study should be performed to determine if adjunctive surgery is as mandatory 
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as it has been cited to be. Several case reports have already shown that optimal 
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Appendix A. Candida Endocarditis Data Collection 






Candida Endocarditis Status: Please list prespecified criteria for diagnosis 
Species: 
Initiation Date of Assigned Medication: 
Date of Candidemia Clearance: if applicable 
Date of Candida Endocarditis Clearance: if applicable 





Appendix B. Sample HIC Consent Form 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
200 FR.1 
YALE UNIVERSITY SCHOOL OF MEDICINE 
Study Title: Liposomal Amphotericin B and Flucytosine Versus Micafungin in 
Treatment of Candida Endocarditis 
Principal Investigator: Dr. Matthew Grant, MD 
Co-Investigator: Anton Matthew Yanker, PA-SII 
Funding Source: Yale School of Medicine 
 
Invitation to Participate and Description of Project 
 We are inviting you to participate in a research study designed to look at the 
efficacy of two different antifungal treatments in the setting of Candida Endocarditis. 
You have been asked to participate because you are highly suspected of being 
affected of Candida endocarditis. Approximately 200 individuals will be participating 
in the study. 
 In order to decide whether or not you wish to be a part of this research study, 
you should know enough about its risks and benefits to make an informed decision. 
This consent form gives you detailed information about the research study, which a 
member of the research team will also discuss with you. This discussion should take 
place over all aspects of this research study—its purpose, procedures that will be 
performed, any potential risks of the procedures, possible benefits, and possible 
alternative treatments. Once you understand the study, you will be asked if you wish 
to participate. If you agree, you will be asked to sign this form. 
 
Description of Procedures 
If you agree to participate in this study, you will be randomly assigned to receive 
either (a) liposomal amphotericin B with flucytosine, OR (b) micafungin with 
placebo.  
In this study program, you will be asked to adhere to your assigned medication 
regimen at the prespecified frequency and dosage. The study nurses will be providing 
the medications to you at scheduled times, dosages, and frequencies. You will remain 
in the hospital for the duration of the treatment, which will last no longer than fifty-six 
days. Blood draws will be obtained daily to monitor candidemia levels and to gather 
information about standard laboratory information, such as complete blood counts and 
metabolic panels. Transthoracic and/or transoesophageal echocardiograms will be 
conducted as well to determine the presence of Candida endocarditis. 
Throughout the entirety of the study, the investigators will ask you to document 
and/or report any adverse effects you are feeling that you believe may be a result of 
your study medication regimen. 
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A description of this study will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. (See Clinical Trials Identifier Number xxxxxxxxxx). This 
website will not include information that can identify you. The purpose of this 
database is to allow everyone to see information on what studies are being done, and 
what studies have already been done. At most, the website will include a summary of 
the results. You can search this website at any time. 
You will be told of any significant new findings that are developed during the course 
of your participation in this study that may affect your willingness to continue to 
participate. Research results will not be returned to your clinician. If research results 
are published, your name and other personal information will not be disclosed or 
given. 
 
Risks and Inconveniences 
Liposomal amphotericin B has been used for several years and studied in a number of 
clinical trials for many fungal infections. The most common adverse effect is 
nephrotoxicity and infusion-related events. Flucytosine has also been used for several 
years and studied in a number of clinical trials. The most common adverse effect is 
myelotoxicity after prolonged usage. Therapeutic-drug monitoring will be conducted 
to watch for serious adverse effects; however, we would like you to report any 
adverse effects you may be experiencing. 
Micafungin is another antifungal drug that has been used for several years and studied 
in a number of clinical trials. To our knowledge, the resulting adverse effects are 
minimal in severity. 
Other risks from participating in the study include the breach of confidentiality about 
your health status and participation in the study. This is unlikely to happen, as all 
study investigators are trained and certified in research privacy, as well as HIPAA. 
We will also ask you to have your blood drawn daily. The risks involved in 
venepuncture include, but are not limited to, momentary discomfort at the site of the 
blood draw, possible bruising, redness, and swelling around the site, bleeding at the 
site, feeling of lightheadedness when the blood is draw, and rarely, infection at the 
site of venepuncture. 
 
Benefits 
The potential benefit resulting from the study includes full treatment of candidemia 
and/or Candida endocarditis. This study may also provide better insights to treatment 
guidelines for this rare and deadly disease, which may lead to more treatment success 






The medications will be provided to you free of charge. There are no other costs 
associated with your participation in the study. Parking will also be provided free of 
charge to visitors. 
 
Treatment Alternatives/Alternatives 
If you choose not to participate in this study, there are no alternative treatments 
available, except those that are already being administered by your treatment team, 
including pharmacotherapy (medications/drugs). You may choose not to participate. 
 
Confidentiality and Privacy 
Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or 
State law. Examples of information that we are legally required to disclose include 
abuse of a child, abuse of an elderly person, or certain reportable diseases. 
Information will be kept confidential by using only identification numbers on study 
forms, storing signs forms in locked cabinets, and password protecting data to be 
stored on a computer. When the results of the research are published or discussed in 
conferences, no information will be included that would reveal your identity unless 
your specific permission for this activity is obtained. 
We understand that information about your health is personal and we are committed 
to protecting the privacy of that information. If you decide to be in this study, the 
researcher will get information that identifies your personal health information. This 
may include information that might directly identify you, such as name, address, 
telephone number, email address, and/or mobile phone number. This information will 
be de-identified at the earliest reasonable time after we receive it, meaning we will 
replace your identifying information with a code that does not directly identify you. 
The principal investigator will keep a link that identifies you and your coded 
information. This link will be kept secure and available only to the principal 
investigator, or selected members of the research team. Any information that can 
identify you will remain confidential. Information will be kept confidential by using 
only identification numbers on study forms, storing signed forms in locked cabinets, 
and password protecting data stored on a computer. The research team will only give 
this coded information to others to carry out this research study. The link to your 
personal information will be kept for five years. After five years, the link will be 
destroyed, and the data will become anonymous. The data will be kept in this 
anonymous form indefinitely. 
The information about your health that will be collected in this study includes: 
• Research study records 
• Records about phone calls made as part of this research 
• Records about your study visits 
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Information about your health, which might identify your child, may be used or given 
to: 
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale University, the Yale Human Research Protection 
Program, and the Yale Human Investigation Committee (the committee that 
reviews, approves, and monitors research on human subjects), who are 
responsible for ensuring research compliance. These individuals are required 
to keep all information confidential. 
• Those individuals at Yale who are responsible for the financial oversight of 
research, including billings and payments. 
• The Principal Investigator, Dr. Matthew Grant 
• Co-Investigators and other investigators 
• Study Coordinator and members of the research team 
By signing this form, you authorize the use and/or disclosure of the information 
described above for this research study. The purpose for the uses and disclosures you 
are authorizing is to ensure that the information relating to this research is available to 
all parties who many need it for research purposes. 
All healthcare providers subject to the Health Insurance Portability and 
Accountability Act (HIPAA) are required to protect the privacy of your information. 
The research staff at the Yale School of Medicine are required to comply with HIPAA 
and to ensure the confidentiality of you or your child’s information. 
If you choose to participate in this study, the investigators will check your electronic 
medical record at Yale via EPIC to make sure you qualify. Any access to your 
electronic medical record will be done consistent with HIPAA regulations. 
Some of the individuals or agencies listed above may not be subject to HIPAA, and 
therefore, may not be required to provide the same confidentiality protection. They 
could use or disclose your information in ways not mentioned in this form. However, 
to better protect your health information, agreements are in place with these 
individuals and/or companies that require that they keep your information 
confidential. 
You have the right to review and copy your health information in your medical record 
in accordance with institutional medical records policies. This authorization to use 
and disclose your health information collected during your participation in this study 
will never expire. 
 
Voluntary Participation and Withdrawal 
You are free to choose not to participate in this study. Your healthcare outside the 
study, the payment for your healthcare, and your healthcare benefits will not be 
affected if you do not agree to participate. However, you will not be able to enrol in 
this research study and will not receive study procedures as a study participant if you 
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do not allow use of your information as part of this study. You do not give up any of 
your legal rights by signing this form. 
 
Withdrawing from the Study 
If you do not become a subject, you are free to stop and withdraw from this study at 
any time during its course. 
To withdraw from the study, you can call a member of the research time at any time 
and tell him or her that you no longer wish to participate. This will cancel any future 
appointments. 
The researchers may withdraw you from participating in the research, if necessary. 
This will only occur if you do not adhere to the assigned treatment. 
If you choose not to participate, or if you withdraw, it will not harm your relationship 
with your treatment team, or with the Yale School of Medicine and Yale New Haven 
Hospital. 
 
Withdrawing Your Authorization to Use and Disclose Your Health Information 
You may withdraw or take away permission to use and disclose your health 
information at any time. You do this by calling or sending written notice to the 
Principal Investigator, Dr. Matthew Grant. 
When you withdraw your permission, no new health information identifying you will 
be gathered after that date. Information that has already been gathered may still be 
used and given to others until the end of the research study, as necessary to ensure the 
integrity of the study and/or study oversight. 
You do not give up any of your legal rights by signing this form. 
 
Questions 
We have used technical and/or legal terms in this form. Please feel free to ask about 
anything you do not understand and to consider this research and the permission form 





I have read, or someone has read to me, this form and have decided to participate in 
the project described above. Its general purpose, the specifics of my involvement, 
possible hazards, and possible inconveniences have been explained to my satisfaction. 
My signature indicates that I, ____________________, have received a copy of this 
consent form. 





__________________________________  ____________________ 
Signature of Person Obtaining Consent  Date 
 
If you have any further questions about this project, or if you have a research-related 
problem, you may contact the Principal Investigator, Dr. Matthew Grant at (xxx) xxx-
xxxx. 
After signing this form, if you have any questions about your privacy rights, please 
contact the Yale Privacy Officer at (xxx) xxx-xxxx. If you would like to talk to 
someone other than the researchers to discuss problems, concerns, and/or questions 
you may have regarding the research, or to discuss your rights as a research subject, 
you may contact the Yale Human Investigator Committee at (xxx) xxx-xxxx.
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